Product Image

Contributor Information

  • Name Anne-Marie Mes-Masson and Diane Provencher
  • Institute Centre Hospitalier de L’université de Montréal
  • Primary citation Sauriol A et al. 2020. Cancers. 12(8):2222. PMID: 32784519

Tool Details

  • Tool name: TOV-2835EP cell line
  • Alternate names: TOV-2835EP
  • Tool type: Cell Lines
  • Organism: Human
  • Donor: Grade 3 – Stage III; Mutations: TP53 Exon 8; Carboplatin/Taxol
  • Tissue: Derived from solid tumor of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
  • Gender: Female
  • Cancer type: Lung cancer
  • Morphology: Characteristic flattened cobbleston-like appearance. Formed loose aggregates rather than solid spheroids
  • Growth properties: Adherent
  • CRISPR: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from metastases at the omentum (EP) at specific time points at diagnosis and relapse. Cell line exhibits intermediate sensitivity to carboplatin and did not form SC or IP tumors in NRG mice
  • Research area: Cancer
  • Production details: Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly.
  • Additional notes: Patient 2835 was diagnosed at age 62 with no prior history of cancer. Patient received treatment with Carboplatin and Paclitaxel prior to sampling and sampling was done in

  • For Research Use Only

Target Details

Application Details

Handling

  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Temperature: 37C
  • Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
  • Cultured in antibiotics?: Amphotericin B and Gentamicin

Documentation

Related Tools

Product Image

Mitochondrial complex II mutated SDHD cell line

#160706
Product Image

TERT/E6/E7 chondrocyte cell line

#154451
Product Image

HEK293-A mRFP-ATG9 Cell Line

#151828

References

  • •  Gaia-Oltean et al. 2021. Exp Ther Med. 21(3):243. PMID: 33603851 Canals Hernaez et al. 2020. J Immunother Cancer. 8(2):e001128. PMID: 33243933 Borzdzi?owska et al. 2022. Biomedicines. 11
  • •  10(5):1116. PMID: 35625852 Meng et al. 2023. J Anim Sci. 3
  • •  101:skad215. PMID: 37351870 Koni et al. 2020. Int J Mol Sci. 18
  • •  21(20):7697. PMID: 33080952